The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
SOLO1 versus SOLO2: Cost-effectiveness of olaparib as maintenance therapy for newly diagnosed and platinum-sensitive recurrent ovarian carcinoma among women with germline BRCA mutations (gBRCAmut).
 
Juliet Elizabeth Wolford
Consulting or Advisory Role - Tesaro
 
Krishnansu Sujata Tewari
Honoraria - Clovis Oncology; Tesaro
Consulting or Advisory Role - Roche/Genentech
Speakers' Bureau - AstraZeneca; Merck; Roche/Genentech
Research Funding - Abbvie (Inst); Genentech/Roche (Inst); Merck (Inst); Morphotek (Inst); Regeneron (Inst)
Travel, Accommodations, Expenses - Roche/Genentech
 
Su-Ying Liang
No Relationships to Disclose
 
Jiaru Bai
No Relationships to Disclose
 
Amandeep Kaur Mann
No Relationships to Disclose
 
Kathleen N. Moore
Consulting or Advisory Role - Advaxis; Aravive; AstraZeneca; Clovis Oncology; Genentech/Roche; Immunogen; Janssen Oncology; Merck; OncoMed; Pfizer/EMD Serono; Samumed; TESARO; VBL Therapeutics
Speakers' Bureau - AstraZeneca
Research Funding - Abbvie/Stemcentrx (Inst); Advaxis (Inst); Agenus (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Forty Seven (Inst); Genentech (Inst); Immunogen (Inst); Lilly (Inst); Lilly Foundation (Inst); Merck (Inst); Novartis Pharmaceuticals UK Ltd. (Inst); Novogen (Inst); PTC Therapeutics (Inst); Regeneron (Inst); Stem CentRx (Inst); Takeda (Inst); Tesaro (Inst); Verastem (Inst)
Travel, Accommodations, Expenses - Genentech/Roche
Other Relationship - AstraZeneca
 
Eric Pujade-Lauraine
Honoraria - AstraZeneca; Tesaro
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Incyte; Merck; Pfizer/EMD Serono; Roche; TESARO
Travel, Accommodations, Expenses - AstraZeneca; Roche; Tesaro
Other Relationship - Arcagy-Gineco
 
Jonathan A. Ledermann
Honoraria - AstraZeneca/MedImmune; Roche
Consulting or Advisory Role - Artios; AstraZeneca/MedImmune; Clovis Oncology; Cristal Therapeutics; Merck; Pfizer; Seagen; Tesaro
Speakers' Bureau - Clovis Oncology; Pfizer
Research Funding - AstraZeneca (Inst); MSD Oncology (Inst)
 
Bradley J. Monk
Leadership - US Oncology
Honoraria - Abbvie; Advaxis; Amgen; Amgen; AstraZeneca; Bayer; Biodesix; Biodesix; Clovis Oncology; Genmab; GlaxoSmithKline; Gradalis; Immunogen; Incyte; Insys Therapeutics; Janssen; Mateon Therapeutics; Merck; Myriad Pharmaceuticals; Nucana; Oxigene; Oxigene; Perthera; Pfizer; Precision Oncology; Roche/Genentech; Samumed; Samumed; Takeda; Tesaro; VBL Therapeutics
Consulting or Advisory Role - Abbvie; Advaxis; Amgen; AstraZeneca; Bayer; Biodesix; Cerulean Pharma; Clovis Oncology; GlaxoSmithKline; Gradalis; Immunogen; Incyte; Insys Therapeutics; Mateon Therapeutics; Merck; Myriad Pharmaceuticals; Nucana; Oxigene; Perthera; Pfizer; Precision Oncology; Roche/Genentech; Tesaro; Verastem; Vermillion
Speakers' Bureau - AstraZeneca; Clovis Oncology; Janssen; Roche/Genentech; Tesaro
Research Funding - Advaxis (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Genentech (Inst); Immunogen (Inst); Janssen (Inst); Lilly (Inst); Morphotek (Inst); Novartis (Inst); Nucana (Inst); Pfizer (Inst); Regeneron (Inst); Tesaro (Inst)
 
John K. Chan
Honoraria - AstraZeneca; Clovis Oncology; Genentech/Roche; Tesaro
Consulting or Advisory Role - AstraZeneca; Biodesix; Clovis Oncology; Janssen Oncology; Mateon Therapeutics; Roche/Genentech; Tesaro
Speakers' Bureau - AstraZeneca; Clovis Oncology; Roche/Genentech; Tesaro
Research Funding - AstraZeneca (Inst); Roche/Genentech (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Clovis Oncology; Roche/Genentech; Tesaro